Patents by Inventor Michael R. Klass

Michael R. Klass has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20020035244
    Abstract: A set of contiguous and partially overlapping RNA sequences and polypeptides encoded thereby, designated as PS215 and transcribed from prostate tissue is described. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the prostate such as prostate cancer. Also provided are antibodies which specifically bind to PS215-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific PS215 polypeptide, which molecules are useful for the therapeutic treatment of prostate diseases, tumors or metastases.
    Type: Application
    Filed: September 9, 1997
    Publication date: March 21, 2002
    Inventors: MAURICE COHEN, TRACEY L. COLPITTS, PAULA N. FRIEDMAN, EDWARD N. GRANADOS, MICHAEL R. KLASS, JOHN C. RUSSELL, STEVEN D. STROUPE
  • Patent number: 6350583
    Abstract: A set of contiguous and partially overlapping RNA sequences and polypeptides encoded thereby, designated as PS190 and transcribed from prostate tissue is described. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the prostate, such as prostate cancer. Also provided are antibodies which specifically bind to PS190-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific PS190 polypeptide, which molecules are useful for the therapeutic treatment of prostate diseases, tumors or metastases.
    Type: Grant
    Filed: May 8, 2000
    Date of Patent: February 26, 2002
    Assignee: Abbott Laboratories
    Inventors: Maurice Cohen, Tracey L. Colpitts, Paula N. Friedman, Edward N. Granados, Michael R. Klass, John C. Russell, Stephen D. Stroupe
  • Publication number: 20020018990
    Abstract: A set of contiguous and partially overlapping cDNA sequences and polypeptides encoded thereby, designated as BS124 and transcribed from breast tissue, is described. These sequences are useful for detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the breast, such as breast cancer. Also provided are antibodies which specifically bind to a BS124-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific BS124 polypeptide, which molecules are useful for the therapeutic treatment of breast diseases, tumors or metastases.
    Type: Application
    Filed: June 19, 1998
    Publication date: February 14, 2002
    Inventors: PATRICIA A. BILLING-MEDEL, MAURICE COHEN, TRACEY L. COLPITTS, PAULA N. FRIEDMAN, JULIAN GORDON, EDWARD N. GRANADOS, STEVEN C. HODGES, MICHAEL R. KLASS, JON D. KRATOCHVIL, JOHN C. RUSSELL, CHRISTI P. SCHEFFEL, STEPHEN D. STROUPE, HONG YU
  • Publication number: 20010055758
    Abstract: A set of contiguous and partially overlapping cDNA sequences and polypeptides encoded thereby, designated as PS118 and transcribed from prostate tissue, is described. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the prostate, such as prostate cancer. Also provided are antibodies which specifically bind to PS118-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific PS118 polypeptide, which molecules are useful for the therapeutic treatment of prostate diseases, tumors or metastases.
    Type: Application
    Filed: April 23, 1998
    Publication date: December 27, 2001
    Inventors: PATRICIA A. BILLING-MEDEL, MAURICE COHEN, TRACEY L. COPLPITTS, PAULA N. FRIEDMAN, JULIAN GORDON, EDWARD N. GRANADOS, STEVEN C. HODGES, MICHAEL R. KLASS, JON D. KRATOCHVIL, LISA ROBERTS-RAPP, JOHN C. RUSSELL, STEPHEN D. STROUPE
  • Publication number: 20010010904
    Abstract: A set of contiguous and partially overlapping cDNA sequences and polypeptides encoded thereby, designated as CS 198 and transcribed from GI tract tissue, is described. These sequences are useful for detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the GI tract, such as GI tract cancer. Also provided are antibodies which specifically bind to CS 198-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific CS 198 polypeptide, which molecules are useful for the therapeutic treatment of GI tract diseases, tumors or metastases.
    Type: Application
    Filed: March 30, 1998
    Publication date: August 2, 2001
    Inventors: PATRICIA A. BILLING-MEDEL, MAURICE COHEN, TRACEY L. COLPITTS, PAULA N. FRIEDMAN, JULIAN GORDON, EDWARD N. GRANADOS, MARK HAYDEN, STEVEN C. HODGES, MICHAEL R. KLASS, JON D. KRATOCHVIL, LISA ROBERTS-RAPP, JOHN C. RUSSELL, STEPHEN D. STROUPE
  • Patent number: 6252047
    Abstract: A set of contiguous and partially overlapping cDNA sequences and polypeptides encoded thereby, designated as PS108 and transcribed from prostate tissue, is described. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, in vivo imaging, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the prostate, such as prostate cancer. Also provided are antibodies which specifically bind to PS108-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific PS108 polypeptide, which molecules are useful for the therapeutic treatment of prostate diseases, tumors or metastases.
    Type: Grant
    Filed: March 15, 2000
    Date of Patent: June 26, 2001
    Assignee: Abbott Laboratories
    Inventors: Patricia A. Billing-Medel, Maurice Cohen, Tracey L. Colpitts, Paula N. Friedman, Julian Gordon, Edward N. Granados, Steven C. Hodges, Michael R. Klass, Jon D. Kratochvil, Lisa Roberts-Rapp, John C. Russell, Stephen D. Stroupe, Hong Yu
  • Patent number: 6232456
    Abstract: A set of contiguous and partially overlapping RNA sequences and polypeptides encoded thereby, designated as PS133 and transcribed from prostate tissue is described. One polypeptide of the present invention is a member of the human serine protease family. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the prostate, such as prostate cancer. Also provided are antibodies which specifically bind to PS133-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific PS133 polypeptide, which molecules are useful for the therapeutic treatment of prostate diseases, tumors or metastases.
    Type: Grant
    Filed: October 6, 1997
    Date of Patent: May 15, 2001
    Assignee: Abbott Laboratories
    Inventors: Maurice Cohen, Tracey L. Colpitts, Paula N. Friedman, Edward Granados, Michael R. Klass, John C. Russell, Kent D. Stewart, Stephen D. Stroupe
  • Patent number: 6207380
    Abstract: Polypeptides and polynucleotides useful for detecting, diagnosing, staging, monitoring, prognosticating, in vivo imaging, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the urinary tract, such as urinary cancer, are described. These sequences are derived from keratin/cytokeratin, CAS, or mat-8 polypeptides and polynucleotides. Also provided are antibodies which specifically bind to keratin/cytokeratin, CAS, or mat-8-encoded polypeptides or proteins, which molecules are useful for the therapeutic treatment of urinary tract diseases, tumors or metastases.
    Type: Grant
    Filed: September 15, 1998
    Date of Patent: March 27, 2001
    Assignee: Abbott Laboratories
    Inventors: Patricia A. Billing-Medel, Maurice Cohen, Paula N. Friedman, Julian Gordon, Steven C. Hodges, Michael R. Klass, Jon D. Kratochvil, Eric Russell, Stephen D. Stroupe
  • Patent number: 6183952
    Abstract: A novel member of the uteroglobin family of proteins, designated as BU101, is described. BU101 is defined by a set of contiguous and partially overlapping RNA sequences transcribed from breast tissue, and polypeptides encoded thereby. A fully sequenced clone representing the longest continuous sequence of BU101 is also disclosed. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the breast such as breast cancer. Also provided are antibodies which specifically bind to BU101-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific BU101 polypeptide, which molecules are useful for the therapeutic treatment of breast diseases, tumors or metastases.
    Type: Grant
    Filed: August 15, 1997
    Date of Patent: February 6, 2001
    Assignee: Abbott Laboratories
    Inventors: Patricia A. Billing-Medel, Maurice Cohen, Tracey L. Colpitts, Paula N. Friedman, Julian Gordon, Edward N. Granados, Steven C. Hodges, Michael R. Klass, Jon D. Kratochvil, Lisa Roberts-Rapp, John C. Russell, Stephen D. Stroupe
  • Patent number: 6130043
    Abstract: A set of contiguous and partially overlapping cDNA sequences and polypeptides encoded thereby, designated as PS108 and transcribed from prostate tissue, is described. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, in vivo imaging, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the prostate, such as prostate cancer. Also provided are antibodies which specifically bind to PS108-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific PS108 polypeptide, which molecules are useful for the therapeutic treatment of prostate diseases, tumors or metastases.
    Type: Grant
    Filed: May 1, 1998
    Date of Patent: October 10, 2000
    Assignee: Abbott Laboratories
    Inventors: Patricia A. Billing-Medel, Maurice Cohen, Tracey L. Colpitts, Paula N. Friedman, Julian Gordon, Edward N. Granados, Steven C. Hodges, Michael R. Klass, Jon D. Kratochvil, Lisa Roberts-Rapp, John C. Russell, Stephen D. Stroupe, Hong Yu
  • Patent number: 6110675
    Abstract: A set of contiguous and partially overlapping RNA sequences and polypeptides encoded thereby, designated as PS112 and transcribed from prostate tissue is described. A fully sequenced clone representing a continuous sequence of PS112 is also disclosed. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the prostate, such as prostate cancer. Also provided are antibodies which specifically bind to PS112-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific PS112 polypeptide, which molecules are useful for the therapeutic treatment of prostate diseases, tumors or metastases.
    Type: Grant
    Filed: October 8, 1997
    Date of Patent: August 29, 2000
    Assignee: Abbott Laboratories
    Inventors: Maurice Cohen, Paula N. Friedman, Julian Gordon, Steven C. Hodges, Michael R. Klass, Jon D. Kratochvil, Lisa Roberts-Rapp, John C. Russell, Stephen D. Stroupe, Hong Yu
  • Patent number: 5939265
    Abstract: A set of contiguous and partially overlapping RNA sequences and polypeptides encoded thereby, designated as LU103 and transcribed from lung tissue is described. A fully sequenced clone representing the longest continuous sequence of LU103 is also disclosed. These sequences are useful for detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the lung such as lung cancer.
    Type: Grant
    Filed: November 5, 1997
    Date of Patent: August 17, 1999
    Assignee: Abbott Laboratories
    Inventors: Maurice Cohen, Paula N. Friedman, Julian Gordon, Steven C. Hodges, Michael R. Klass, Jon D. Kratochvil, Lisa Roberts-Rapp, John C. Russell, Steven D. Stroupe
  • Patent number: 5919638
    Abstract: A set of contiguous and partially overlapping oligonucleotide sequences transcribed from a prostate. Also provided are human disease-specific polypeptides translated from said oligonucleotide sequences and a procedure for producing such polypeptide by recombinant techniques. Antibodies, antagonists and inhibitors of such polypeptide which may be used to prevent the action of such polypeptide and therefore may be used therapeutically to treat prostate diseases, tumors or metastastases are disclosed. Also disclosed is the use of said antibodies, agonists and inhibitors as well as the nucleic acid sequences to screen for, diagnose, prognose, stage and monitor conditions and diseases attributable to prostate tumor, especially prostate cancer. The use of said partial sequence to provide antibodies, agonists and inhibitors as well as partial nucleic acid sequences to screen for, diagnose, stage and monitor diseases and associated with prostate tumor.
    Type: Grant
    Filed: October 8, 1996
    Date of Patent: July 6, 1999
    Assignee: Abbott Laboratories
    Inventors: John C. Russell, Maurice Cohen, Paula N. Friedman, Michael R. Klass, Lisa Roberts-Rapp